MCIM
STSA

Meadow Creek Investment Management’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Meadow Creek Investment Management’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$28K Buy
+1,876
New +$29.1K ﹤0.01% 1301

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return

Meadow Creek Investment Management's STSA Position: Q3 2019 in Review

Meadow Creek Investment Management opened a new position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q3 2019: 1,876 shares worth $28K. The stake represents ﹤0.01% of the portfolio and ranks #1301 among its holdings.

30 funds tracked by Wall St. Rank hold STSA as of Q3 2019.

  • Meadow Creek Investment Management held 1,876 shares of Satsuma Pharmaceuticals, Inc. Common Stock worth $28K as of Q3 2019.
  • Satsuma Pharmaceuticals, Inc. Common Stock was a new Meadow Creek Investment Management position in Q3 2019.
  • Satsuma Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1301 holding.
  • 30 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.